Q-omics provides the consensus-scored PSAT1P3 profile across patient tissues and cancer cell-line models. PSAT1P3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PSAT1P3 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, PSAT1P3 RNA expression shows 13,863 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, COAD, and THYM as cancer lineages where PSAT1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSAT1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSAT1P3 survival associations across molecular data types. PSAT1P3 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSAT1P3 RNA expression–survival associations across cancer types. High PSAT1P3 expression shows unfavorable associations in LUAD, OV and THCA, but favorable associations in HNSC, GBM and LUSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for PSAT1P3 RNA expression.
This table summarizes PSAT1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PSAT1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSAT1P3 shows lower tumor expression in BRCA and higher tumor expression in COAD, UCEC, LUAD and KICH. The COAD box plot shows higher PSAT1P3 RNA expression in tumor versus normal tissue (log2 FC = +0.200, t-test p < 0.001).
This table shows molecular features associated with PSAT1P3 in patient tissues and cancer cell lines. In patient samples, PSAT1P3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
